We have located links that may give you full text access.
Journal Article
Review
Antibody drug conjugates: lessons from 20 years of clinical experience.
Antibody drug conjugates are complex delivery systems for selective delivery of cytotoxic payloads. Yet despite the potential for this therapeutic platform and hundreds of clinical studies only three ADCs have been approved by regulatory agencies and only two are currently marketed. The difficulties for this class of compounds are both categorized and explored in this review, and potential solutions identified.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app